Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Cardiotoxicity 2Breast Neoplasms 2Renal Insufficiency, Chronic 1Kidney Neoplasms 1Heart Failure 1Carcinoma, Renal Cell 1

Interventions

Echocardiography 6Doxorubicin 3Carvedilol 3empagliflozin 2Social Determinants of Health 2High-Intensity Interval Training 2Electrocardiography 2Cyclophosphamide 2pegfilgrastim 1dapagliflozin 1Watchful Waiting 1Vincristine 1Vascular Stiffness 1Trastuzumab 1Tablets 1Standard of Care 1Rosuvastatin Calcium 1Rituximab 1Resistance Training 1Pulse Wave Analysis 1Prednisolone 1Palliative Care 1Observation 1Methods 1Lenalidomide 1Hematologic Tests 1Fenofibrate 1Exercise Test 1Environmental Biomarkers 1EGFR tyrosine kinase inhibitor 324674 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cardiotoxicity × empagliflozin × 1 year × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

NCT05271162 2025-11-21

EMPACT

Maria Sklodowska-Curie National Research Institute of Oncology

Phase 3 Recruiting
220 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡